A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic

Elena Dragioti; Han Li; George Tsitsas; Keum Hwa Lee; Jiwoo Choi; Jiwon Kim; Young Jo Choi; Konstantinos Tsamakis; Andrés Estradé; Agorastos Agorastos; Davy Vancampfort; Dimitrios Tsiptsios; Trevor Thompson; Anna Mosina; Georgios Vakadaris; Paolo Fusar-Poli; Andre F. Carvalho; Christoph U. Correll; Young Joo Han; Seoyeon Park; Jae Il Shin; Marco Solmi

doi:10.1002/jmv.27549

A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic

Elena Dragioti, Han Li, George Tsitsas, Keum Hwa Lee, Jiwoo Choi, Jiwon Kim, Young Jo Choi, Konstantinos Tsamakis, Andrés Estradé, Agorastos Agorastos, Davy Vancampfort, Dimitrios Tsiptsios, Trevor Thompson, Anna Mosina, Georgios Vakadaris, Paolo Fusar-Poli, Andre F. Carvalho, Christoph U. Correll, Young Joo Han, Seoyeon ParkJae Il Shin, Marco Solmi

Department of Pediatrics

Research output: Contribution to journal › Article › peer-review

Abstract

The COVID-19 pandemic and related restrictions can impact mental health. To quantify the mental health burden of COVID-19 pandemic, we conducted a systematic review and meta-analysis, searching World Health Organization COVID-19/PsycInfo/PubMed databases (09/29/2020), including observational studies reporting on mental health outcomes in any population affected by COVID-19. Primary outcomes were the prevalence of anxiety, depression, stress, sleep problems, posttraumatic symptoms. Sensitivity analyses were conducted on severe mental health problems, in high-quality studies, and in representative samples. Subgroup analyses were conducted stratified by age, sex, country income level, and COVID-19 infection status. One-hundred-seventy-three studies from February to July 2020 were included (n = 502,261, median sample = 948, age = 34.4 years, females = 63%). Ninety-one percent were cross-sectional studies, and 18.5%/57.2% were of high/moderate quality. The highest prevalence emerged for posttraumatic symptoms in COVID-19 infected people (94%), followed by behavioral problems in those with prior mental disorders (77%), fear in healthcare workers (71%), anxiety in caregivers/family members of people with COVID-19 (42%), general health/social contact/passive coping style in the general population (38%), depression in those with prior somatic disorders (37%), and fear in other-than-healthcare workers (29%). Females and people with COVID-19 infection had higher rates of almost all outcomes; college students/young adults of anxiety, depression, sleep problems, suicidal ideation; adults of fear and posttraumatic symptoms. Anxiety, depression, and posttraumatic symptoms were more prevalent in low-/middle-income countries, sleep problems in high-income countries. The COVID-19 pandemic adversely impacts mental health in a unique manner across population subgroups. Our results inform tailored preventive strategies and interventions to mitigate current, future, and transgenerational adverse mental health of the COVID-19 pandemic.

Original language	English
Pages (from-to)	1935-1949
Number of pages	15
Journal	Journal of Medical Virology
Volume	94
Issue number	5
DOIs	https://doi.org/10.1002/jmv.27549
Publication status	Published - 2022 May

Bibliographical note

Funding Information:
C. U. C. has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante‐ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. A. A. has received honoraria and travel support from Janssen‐Cilag, Bausch Health, ELPEN, and Lundbeck in the past 2 years. The remaining authors declare that they have no conflict of interests.

Publisher Copyright:
© 2021 Wiley Periodicals LLC

All Science Journal Classification (ASJC) codes

Virology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jmv.27549

Cite this

Dragioti, E., Li, H., Tsitsas, G., Lee, K. H., Choi, J., Kim, J., Choi, Y. J., Tsamakis, K., Estradé, A., Agorastos, A., Vancampfort, D., Tsiptsios, D., Thompson, T., Mosina, A., Vakadaris, G., Fusar-Poli, P., Carvalho, A. F., Correll, C. U., Han, Y. J., ... Solmi, M. (2022). A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic. Journal of Medical Virology, 94(5), 1935-1949. https://doi.org/10.1002/jmv.27549

Dragioti, Elena ; Li, Han ; Tsitsas, George ; Lee, Keum Hwa ; Choi, Jiwoo ; Kim, Jiwon ; Choi, Young Jo ; Tsamakis, Konstantinos ; Estradé, Andrés ; Agorastos, Agorastos ; Vancampfort, Davy ; Tsiptsios, Dimitrios ; Thompson, Trevor ; Mosina, Anna ; Vakadaris, Georgios ; Fusar-Poli, Paolo ; Carvalho, Andre F. ; Correll, Christoph U. ; Han, Young Joo ; Park, Seoyeon ; Il Shin, Jae ; Solmi, Marco. / A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic. In: Journal of Medical Virology. 2022 ; Vol. 94, No. 5. pp. 1935-1949.

@article{596b5c5c1b6e401c9d7905522bec4619,

title = "A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic",

abstract = "The COVID-19 pandemic and related restrictions can impact mental health. To quantify the mental health burden of COVID-19 pandemic, we conducted a systematic review and meta-analysis, searching World Health Organization COVID-19/PsycInfo/PubMed databases (09/29/2020), including observational studies reporting on mental health outcomes in any population affected by COVID-19. Primary outcomes were the prevalence of anxiety, depression, stress, sleep problems, posttraumatic symptoms. Sensitivity analyses were conducted on severe mental health problems, in high-quality studies, and in representative samples. Subgroup analyses were conducted stratified by age, sex, country income level, and COVID-19 infection status. One-hundred-seventy-three studies from February to July 2020 were included (n = 502,261, median sample = 948, age = 34.4 years, females = 63%). Ninety-one percent were cross-sectional studies, and 18.5%/57.2% were of high/moderate quality. The highest prevalence emerged for posttraumatic symptoms in COVID-19 infected people (94%), followed by behavioral problems in those with prior mental disorders (77%), fear in healthcare workers (71%), anxiety in caregivers/family members of people with COVID-19 (42%), general health/social contact/passive coping style in the general population (38%), depression in those with prior somatic disorders (37%), and fear in other-than-healthcare workers (29%). Females and people with COVID-19 infection had higher rates of almost all outcomes; college students/young adults of anxiety, depression, sleep problems, suicidal ideation; adults of fear and posttraumatic symptoms. Anxiety, depression, and posttraumatic symptoms were more prevalent in low-/middle-income countries, sleep problems in high-income countries. The COVID-19 pandemic adversely impacts mental health in a unique manner across population subgroups. Our results inform tailored preventive strategies and interventions to mitigate current, future, and transgenerational adverse mental health of the COVID-19 pandemic.",

author = "Elena Dragioti and Han Li and George Tsitsas and Lee, {Keum Hwa} and Jiwoo Choi and Jiwon Kim and Choi, {Young Jo} and Konstantinos Tsamakis and Andr{\'e}s Estrad{\'e} and Agorastos Agorastos and Davy Vancampfort and Dimitrios Tsiptsios and Trevor Thompson and Anna Mosina and Georgios Vakadaris and Paolo Fusar-Poli and Carvalho, {Andre F.} and Correll, {Christoph U.} and Han, {Young Joo} and Seoyeon Park and {Il Shin}, Jae and Marco Solmi",

note = "Funding Information: C. U. C. has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante‐ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. A. A. has received honoraria and travel support from Janssen‐Cilag, Bausch Health, ELPEN, and Lundbeck in the past 2 years. The remaining authors declare that they have no conflict of interests. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",

year = "2022",

month = may,

doi = "10.1002/jmv.27549",

language = "English",

volume = "94",

pages = "1935--1949",

journal = "Journal of Medical Virology",

issn = "0146-6615",

publisher = "Wiley-Liss Inc.",

number = "5",

}

Dragioti, E, Li, H, Tsitsas, G, Lee, KH, Choi, J, Kim, J, Choi, YJ, Tsamakis, K, Estradé, A, Agorastos, A, Vancampfort, D, Tsiptsios, D, Thompson, T, Mosina, A, Vakadaris, G, Fusar-Poli, P, Carvalho, AF, Correll, CU, Han, YJ, Park, S, Il Shin, J & Solmi, M 2022, 'A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic', Journal of Medical Virology, vol. 94, no. 5, pp. 1935-1949. https://doi.org/10.1002/jmv.27549

A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic. / Dragioti, Elena; Li, Han; Tsitsas, George; Lee, Keum Hwa; Choi, Jiwoo; Kim, Jiwon; Choi, Young Jo; Tsamakis, Konstantinos; Estradé, Andrés; Agorastos, Agorastos; Vancampfort, Davy; Tsiptsios, Dimitrios; Thompson, Trevor; Mosina, Anna; Vakadaris, Georgios; Fusar-Poli, Paolo; Carvalho, Andre F.; Correll, Christoph U.; Han, Young Joo; Park, Seoyeon; Il Shin, Jae; Solmi, Marco.

In: Journal of Medical Virology, Vol. 94, No. 5, 05.2022, p. 1935-1949.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic

AU - Dragioti, Elena

AU - Li, Han

AU - Tsitsas, George

AU - Lee, Keum Hwa

AU - Choi, Jiwoo

AU - Kim, Jiwon

AU - Choi, Young Jo

AU - Tsamakis, Konstantinos

AU - Estradé, Andrés

AU - Agorastos, Agorastos

AU - Vancampfort, Davy

AU - Tsiptsios, Dimitrios

AU - Thompson, Trevor

AU - Mosina, Anna

AU - Vakadaris, Georgios

AU - Fusar-Poli, Paolo

AU - Carvalho, Andre F.

AU - Correll, Christoph U.

AU - Han, Young Joo

AU - Park, Seoyeon

AU - Il Shin, Jae

AU - Solmi, Marco

N1 - Funding Information: C. U. C. has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante‐ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. A. A. has received honoraria and travel support from Janssen‐Cilag, Bausch Health, ELPEN, and Lundbeck in the past 2 years. The remaining authors declare that they have no conflict of interests. Publisher Copyright: © 2021 Wiley Periodicals LLC

PY - 2022/5

Y1 - 2022/5

N2 - The COVID-19 pandemic and related restrictions can impact mental health. To quantify the mental health burden of COVID-19 pandemic, we conducted a systematic review and meta-analysis, searching World Health Organization COVID-19/PsycInfo/PubMed databases (09/29/2020), including observational studies reporting on mental health outcomes in any population affected by COVID-19. Primary outcomes were the prevalence of anxiety, depression, stress, sleep problems, posttraumatic symptoms. Sensitivity analyses were conducted on severe mental health problems, in high-quality studies, and in representative samples. Subgroup analyses were conducted stratified by age, sex, country income level, and COVID-19 infection status. One-hundred-seventy-three studies from February to July 2020 were included (n = 502,261, median sample = 948, age = 34.4 years, females = 63%). Ninety-one percent were cross-sectional studies, and 18.5%/57.2% were of high/moderate quality. The highest prevalence emerged for posttraumatic symptoms in COVID-19 infected people (94%), followed by behavioral problems in those with prior mental disorders (77%), fear in healthcare workers (71%), anxiety in caregivers/family members of people with COVID-19 (42%), general health/social contact/passive coping style in the general population (38%), depression in those with prior somatic disorders (37%), and fear in other-than-healthcare workers (29%). Females and people with COVID-19 infection had higher rates of almost all outcomes; college students/young adults of anxiety, depression, sleep problems, suicidal ideation; adults of fear and posttraumatic symptoms. Anxiety, depression, and posttraumatic symptoms were more prevalent in low-/middle-income countries, sleep problems in high-income countries. The COVID-19 pandemic adversely impacts mental health in a unique manner across population subgroups. Our results inform tailored preventive strategies and interventions to mitigate current, future, and transgenerational adverse mental health of the COVID-19 pandemic.

AB - The COVID-19 pandemic and related restrictions can impact mental health. To quantify the mental health burden of COVID-19 pandemic, we conducted a systematic review and meta-analysis, searching World Health Organization COVID-19/PsycInfo/PubMed databases (09/29/2020), including observational studies reporting on mental health outcomes in any population affected by COVID-19. Primary outcomes were the prevalence of anxiety, depression, stress, sleep problems, posttraumatic symptoms. Sensitivity analyses were conducted on severe mental health problems, in high-quality studies, and in representative samples. Subgroup analyses were conducted stratified by age, sex, country income level, and COVID-19 infection status. One-hundred-seventy-three studies from February to July 2020 were included (n = 502,261, median sample = 948, age = 34.4 years, females = 63%). Ninety-one percent were cross-sectional studies, and 18.5%/57.2% were of high/moderate quality. The highest prevalence emerged for posttraumatic symptoms in COVID-19 infected people (94%), followed by behavioral problems in those with prior mental disorders (77%), fear in healthcare workers (71%), anxiety in caregivers/family members of people with COVID-19 (42%), general health/social contact/passive coping style in the general population (38%), depression in those with prior somatic disorders (37%), and fear in other-than-healthcare workers (29%). Females and people with COVID-19 infection had higher rates of almost all outcomes; college students/young adults of anxiety, depression, sleep problems, suicidal ideation; adults of fear and posttraumatic symptoms. Anxiety, depression, and posttraumatic symptoms were more prevalent in low-/middle-income countries, sleep problems in high-income countries. The COVID-19 pandemic adversely impacts mental health in a unique manner across population subgroups. Our results inform tailored preventive strategies and interventions to mitigate current, future, and transgenerational adverse mental health of the COVID-19 pandemic.

UR - http://www.scopus.com/inward/record.url?scp=85122672014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122672014&partnerID=8YFLogxK

U2 - 10.1002/jmv.27549

DO - 10.1002/jmv.27549

M3 - Article

C2 - 34958144

AN - SCOPUS:85122672014

VL - 94

SP - 1935

EP - 1949

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 5

ER -

A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this